Cetera Investment Advisers Invests $245,000 in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Cetera Investment Advisers acquired 44,597 shares of Xeris Biopharma Holdings, Inc., valued at approximately $245,000, during the first quarter of 2023.
• Xeris Biopharma reported earnings of ($0.01) per share, surpassing the consensus estimate, with revenues of $67.71 million for the quarter, also exceeding analyst expectations.
• Research analysts have rated Xeris Biopharma with a consensus rating of "Moderate Buy" and set an average target price of $6.58 for the stock.

Cetera Investment Advisers acquired a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 44,597 shares of the company's stock, valued at approximately $245,000.

Several other institutional investors have also modified their holdings of the stock. Millennium Management LLC lifted its stake in Xeris Biopharma by 34.8% in the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock valued at $6,606,000 after buying an additional 502,853 shares in the last quarter. Nuveen Asset Management LLC lifted its position in shares of Xeris Biopharma by 13.6% in the fourth quarter. Nuveen Asset Management LLC now owns 1,903,442 shares of the company's stock valued at $6,453,000 after acquiring an additional 228,380 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its stake in shares of Xeris Biopharma by 38.4% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,363,452 shares of the company's stock worth $4,622,000 after acquiring an additional 378,437 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Xeris Biopharma by 3.3% in the fourth quarter. Northern Trust Corp now owns 1,196,381 shares of the company's stock worth $4,056,000 after acquiring an additional 38,155 shares during the last quarter. Finally, Driehaus Capital Management LLC purchased a new stake in shares of Xeris Biopharma during the fourth quarter worth approximately $2,014,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Insider Activity at Xeris Biopharma

In other news, Director Dawn Halkuff sold 42,500 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total transaction of $309,400.00. Following the completion of the transaction, the director directly owned 115,000 shares in the company, valued at $837,200. This trade represents a 26.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John Johnson sold 107,500 shares of Xeris Biopharma stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $7.32, for a total value of $786,900.00. Following the completion of the sale, the director directly owned 833,483 shares of the company's stock, valued at $6,101,095.56. The trade was a 11.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.47% of the stock is owned by insiders.

Xeris Biopharma Trading Up 0.3%

XERS traded up $0.02 on Monday, hitting $7.77. The company had a trading volume of 1,953,434 shares, compared to its average volume of 2,553,253. The company's fifty day moving average price is $5.53 and its 200 day moving average price is $4.86. Xeris Biopharma Holdings, Inc. has a 1 year low of $2.48 and a 1 year high of $7.96. The firm has a market cap of $1.25 billion, a P/E ratio of -37.00 and a beta of 0.65.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analyst estimates of $64.58 million. On average, analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on XERS. HC Wainwright assumed coverage on shares of Xeris Biopharma in a research report on Tuesday, August 12th. They issued a "buy" rating and a $10.00 target price for the company. Wall Street Zen upgraded shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. Oppenheimer raised their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Finally, Leerink Partners boosted their target price on Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Tuesday, August 19th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.08.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.